Abivax Climbs 3.56% at Mid-Session, Driven by Quarterly Momentum
Abivax shares are up 3.56% this Wednesday, November 12, at midday, trading at 93.20 euros compared to 90 euros at the previous day's close. Trading volume remains moderate with only 0.06% of the capital traded. This session is part of a very favorable dynamic for the biotech, which significantly outperforms its benchmark index with a rise of 5.55% over seven days and a spectacular gain of 863.8% over one year, compared to 11.07% for the CAC 40 over the same period.
Positive Clinical Trial Results Boost Investor Confidence
The company continues to benefit from the positive reception of clinical results published in early November from its phase 3 Abtect trial evaluating Obefazimod, which demonstrated significant improvement in moderately to severely active ulcerative colitis patients. Today's upward movement accompanies a supportive session for the entire Paris Stock Exchange, with the CAC 40 up 1.14% at 8,248.89 points. Over three months, Abivax has soared 53.54%, confirming investor enthusiasm for the stock since summer announcements. The one-month volatility stands at 17, a high level characteristic of the biotechnological sector, reflecting the sharp movements observed around the publication of clinical results.
Key Data from November 3rd Highlights Efficacy of Obefazimod
The data released on November 3rd revealed that with a daily dose of 50 mg of Obefazimod, 37% of patients experienced no intestinal urgency compared to 18.1% in the placebo group, while 47.6% had no nocturnal stools compared to 24.7% under placebo, with 17.1% of treated patients experiencing remission of fatigue compared to 7.7% under placebo. The stock now consolidates its strong annual progression, having nearly multiplied its value by nine times in twelve months. At 93.20 euros, the price is very close to the resistance threshold of 91.50 euros, which it has just surpassed. The support threshold is significantly lower at 70 euros, offering a comfortable technical maneuvering margin.
Technical Indicators Suggest Sustainable Bullish Momentum
In terms of technical indicators, the RSI stands at 68, approaching the overbought zone without reaching it, suggesting a bullish dynamic that is still sustainable in the short term. Maintenance trial results are expected in the second quarter of 2026 and are intended to support regulatory filings globally. The 50-day moving average at 77.49 euros is well below the current price, confirming the medium-term upward trend, while the 200-day moving average at 32.40 euros reflects the magnitude of the annual movement. The MACD shows a positive configuration with a MACD line at 3.59 above the signal line at 3.19, and a positive histogram at 0.39, validating the continuation of bullish momentum in the absence of new negative catalysts.
